Along with “wet” AMD, Geographic atrophy (GA) is an advanced form of AMD in which large, well-demarcated sections of the retina stop functioning. It leads to irreversible vision loss. Currently, there are no available treatments for GA, but clinical trials of several drugs are showing promise.
GA can occur late in the progression of “dry” AMD, but can also occur even after “wet” AMD has developed and after the use of anti-VEGF injections to stop “wet” AMD. Patients with GA can also develop “wet” AMD.
GA affects more than 5 million people worldwide.
GA accounts for 20% of all legal blindness attributed to AMD.
After age 50, the prevalence of GA quadruples every 10 years.